Valerio Therapeutics SA 2010 IR
The report highlights BioAlliance Pharma's achievements in 2010, including the registration of Oravig in the US and Setofilm in Europe, alongside a strategic partnership with the Therabel Group. Financially, the company experienced a significant increase in net sales to €22.5 million, driven by non-recurring licensing payments, resulting in a net profit of €2.8 million. On the clinical front, BioAlliance Pharma advanced its product pipeline, preparing Sitavir for registration and continuing trials for clonidine Lauriad, AMEP, and fentanyl Lauriad. The company also maintained its commitment to social and environmental responsibility, reporting on employee demographics, health and safety initiatives, and waste management practices in its R&D laboratories.
Company: Valerio Therapeutics SA
Sector: Professional & technical services
Country: France
Year: 2010
Type: IR
Pages: 195
Back to company
Valerio Therapeutics SA
Reference Document
The report highlights BioAlliance Pharma's achievements in 2010, including the registration of Oravig in the US and Setofilm in Europe, alongside a strategic partnership with the Therabel Group. Financially, the company experienced a significant increase in net sales to €22.5 million, driven by non-recurring licensing payments, resulting in a net profit of €2.8 million. On the clinical front, BioAlliance Pharma advanced its product pipeline, preparing Sitavir for registration and continuing trials for clonidine Lauriad, AMEP, and fentanyl Lauriad. The company also maintained its commitment to social and environmental responsibility, reporting on employee demographics, health and safety initiatives, and waste management practices in its R&D laboratories.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2010
Reporting Period
Jan 1, 2010 - Dec 31, 2010
Fiscal Year
2010
Published
Apr 7, 2011
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Employees